3xTG-AD Triple Transgenic Mouse Model

3xTG-AD Triple Transgenic Mouse Model

Overview

3xTG-AD Triple Transgenic Mouse Model

Overview

The 3xTG-AD mouse model is a triple transgenic mouse model of Alzheimer's disease developed by Oddo et al. in 2003[@oddo2003]. It expresses three mutant genes associated with familial AD: [APP](/genes/app) Swedish (KM670/671NL), [MAPT](/genes/mapt) P301L, and [PSEN1](/genes/psen1) M146V. This model is unique in that it develops both amyloid-beta (Abeta) plaques and neurofibrillary tangles (NFTs), making it one of the most valuable tools for studying AD pathogenesis and the interaction between the two hallmark pathologies["@laferla2012"].

The temporal progression of pathology in 3xTG-AD roughly mirrors human disease: Abeta deposits appear first (by 6 months), followed by tau pathology (by 12-15 months), then cognitive decline. This makes the model particularly valuable for studying disease mechanisms and testing therapeutic interventions that target both pathologies["@oddo2003a"].

Genetic Background

Transgene Construction

The 3xTG-AD model contains three human transgenes under neuron-specific Thy1.2 promoter control[@oddo2003]:

| Gene | Mutation | Effect |
|------|----------|--------|
| [APP](/genes/app) | Swedish (K670N/M671L) | 3-4× increased Aβ production |
| [MAPT](/genes/mapt) | P301L | Tau hyperphosphorylation and aggregation |
| [PSEN1](/genes/psen1) | M146V (knock-in) | Enhanced Aβ42/Aβ40 ratio |

APP Swedish Mutation

The Swedish double mutation (K670N/M671L) is located at the β-secretase cleavage site in [APP](/genes/app). It dramatically increases amyloid-beta production, particularly the more aggregation-prone Aβ₁₋₄₂ species[@oddo2003]. The Thy1.2 promoter drives neuron-specific expression, resulting in Aβ accumulation primarily in the brain.

MAPT P301L Mutation

The [MAPT](/genes/mapt) P301L mutation, associated with frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), promotes hyperphosphorylation and aggregation of tau by reducing microtubule binding affinity. Tau pathology develops progressively with age, first in the hippocampus and then spreading to cortical regions[@oddo2004].

PSEN1 M146V Knock-in

The [PSEN1](/genes/psen1) M146V mutation is knocked into the endogenous mouse Psen1 locus, ensuring physiologically appropriate expression levels. This enhances γ-secretase activity, shifting APP processing toward Aβ42 production[@laferla2012].

Background Strain

• Strain: C57BL6/129S mixed background
• Expression: Neuron-specific via Thy1.2 promoter
• Integration: Chromosome integration at unknown locus

Phenotype Characteristics

Amyloid-Beta Plaques

• Onset: 6 months of age[@oddo2004]
• Location: Cortex and hippocampus (subiculum first)
• Type: Mixed Aβ40 and Aβ42, with Aβ42 predominating
• Progression: Increases dramatically with age; by 12 months, extensive plaque burden

Neurofibrillary Tangles

• Onset: 12-15 months of age
• Location: Hippocampus and cortex
• Form: Hyperphosphorylated tau aggregates at multiple epitopes (AT8, AT180, PHF-1)

Synaptic Deficits

Synaptic dysfunction is one of the earliest measurable deficits in the 3xTG-AD model[@singh2015]:

• Early onset: Impaired long-term potentiation (LTP) in hippocampal CA1 by 3-4 months — before plaques or tangles appear
• Structural changes: Reduced dendritic spine density
• Mechanism: Soluble Aβ oligomers accumulate intracellularly and disrupt synaptic function[@billings2005]

Behavioral Phenotype

• Spatial memory: Impaired in Morris water maze by 6 months[@gimenez2009]
• Working memory: Deficits in Y-maze tasks by 9 months
• Anxiety-like behavior: Changes in elevated plus-maze
• Progressive decline: Worsens with age

Neuroinflammation

Microglial Activation

The 3xTG-AD model exhibits robust neuroinflammation, with microglial activation accompanying Aβ and tau pathology. Activated microglia cluster around Aβ plaques, adopting a disease-associated microglia (DAM) phenotype. These microglia attempt to clear Aβ through phagocytosis but may become dysfunctional, contributing to chronic inflammation[@le2014].

Microglial activation can be detected via Iba1 immunohistochemistry, with increased staining density around plaques and in regions of tau pathology. The inflammatory response includes production of cytokines such as IL-1β, TNF-α, and IL-6.

Astrocytosis

Reactive astrocytes are prominent in the 3xTG-AD model. GFAP-positive astrocytes show hypertrophy and increased proliferation in response to neuropathology. Astrocytic responses include both potentially beneficial functions (Aβ sequestration, neurotrophic support) and detrimental effects (excitotoxicity, inflammatory mediator release)[@rodriguez2013].

Metabolic Dysfunction

Mitochondrial Abnormalities

The 3xTG-AD model demonstrates significant mitochondrial dysfunction. Proteomic studies have identified altered expression of mitochondrial proteins involved in energy metabolism, oxidative phosphorylation, and antioxidant defenses. Complex I and IV activity is reduced in aged mice, leading to impaired ATP production[@perez2005].

Glucose Hypometabolism

In vivo imaging studies have demonstrated cerebral glucose hypometabolism in the 3xTG-AD model, similar to patterns observed in human AD patients. PET imaging using fluorodeoxyglucose (FDG) shows reduced glucose uptake in the hippocampus and cortex that correlates with cognitive deficits[@yang2018].

Autophagy and Proteostasis

Autophagy is impaired in the 3xTG-AD model, with accumulation of autophagic vacuoles in neurons. This impairment affects clearance of both Aβ and tau, contributing to protein aggregation. The mTOR pathway shows dysregulation, and restore of autophagy through pharmacological approaches has shown promise in reducing pathology[@zhang2019].

Research Applications

Therapeutic Testing

The 3xTG-AD model is widely used to test[@laferla2012]:

Disease Mechanism Studies

• Amyloid-tau interaction: Cross-seeding and templated propagation studies[@pooler2012]
• Temporal relationships: Determining which pathology drives progression
• Synaptic dysfunction: Early events preceding visible pathology
• Propagation mechanisms: Spreading of pathology through neural circuits

Biomarker Development

• Fluid biomarkers: CSF Aβ and tau correlation with brain pathology
• Imaging biomarkers: PET amyloid and tau binding
• Behavioral correlations: Test performance correlates with neuropathology

Comparison with Other AD Models

| Feature | 3xTG-AD | 5xFAD | APP/PS1 | Tg2576 |
|---------|---------|-------|---------|--------|
| Amyloid plaques | Yes (6 mo) | Yes (2 mo) | Yes (6-9 mo) | Yes (9-12 mo) |
| Neurofibrillary tangles | Yes (12 mo) | Minimal | No | No |
| Dual pathology | Yes | No | No | No |
| Cognitive deficits | 6-12 months | 4-6 months | 8-12 months | 12-15 months |
| Cross-seeding studies | Unique value | No | No | No |

Strengths and Limitations

Strengths

• Dual pathology: Both Aβ and tau pathology in one model — unique among AD mouse models
• Age-dependent progression: Clear temporal progression of pathologies matching human disease
• Early synaptic dysfunction: Measurable deficits before visible pathology
• Cross-seeding studies: Unique ability to study Aβ-tau interactions[@pooler2012]
• Comprehensive platform: Suitable for combination therapy testing

Limitations

• Strain variability: Genetic background affects phenotype expression
• Non-physiological expression: Thy1.2 promoter drives higher than normal transgene levels
• Tau pathology: Less robust neurofibrillary tangles than in human AD — mouse tau does not form true human-style NFTs
• Translation concerns: Murine model cannot fully replicate human AD
• Glial differences: Murine glial responses may differ from human

Experimental Protocols

Recommended Behavioral Battery

• Morris water maze: Spatial learning and memory (6+ months)
• Y-maze: Working memory (6+ months)
• Elevated plus-maze: Anxiety-like behavior
• Novel object recognition: Episodic memory
• Contextual fear conditioning: Associative learning

Histological Protocols

| Target | Markers |
|--------|---------|
| Aβ plaques | 6E10, 4G8, Thioflavin S |
| Tau pathology | AT8, AT180, PHF-1, MC1 |
| Microglia | Iba1, CD68 |
| Astrocytes | GFAP |
| Synapses | Synaptophysin, PSD-95 |

Key Publications

Cross-Links

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [5xFAD Mouse Model](/models/5xfad-mouse)
• [APP Gene](/genes/app)
• [MAPT Protein](/genes/mapt)
• [PSEN1 Gene](/genes/psen1)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology in Neurodegeneration](/mechanisms/tau-pathology-neurodegeneration)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers)
• [MPTP Mouse Model (PD reference)](/models/mptp-mouse-model-parkinsons)